Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
3
75%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (25.0%)
N/A3 (75.0%)

Trials by Status

terminated125%
not_yet_recruiting125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingnot_applicable

Quit-Smoking Study for Native Hawaiians

NCT07075575
terminatednot_applicable

Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial

NCT05528224
completednot_applicable

Reducing Maximal Support in OCD: Efficacy of Stepped-Care Online CBT

NCT06659094
completedphase_4

D-Cycloserine Enhancement of Exposure in Social Phobia

NCT00633984

Clinical Trials (4)

Showing 4 of 4 trials
NCT07075575Not Applicable

Quit-Smoking Study for Native Hawaiians

Not Yet Recruiting
NCT05528224Not Applicable

Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial

Terminated
NCT06659094Not Applicable

Reducing Maximal Support in OCD: Efficacy of Stepped-Care Online CBT

Completed
NCT00633984Phase 4

D-Cycloserine Enhancement of Exposure in Social Phobia

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4